A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : TKIs

Search Conditions:
Search Keyword : TKIs
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: TKIs
Appearance Frequency: 3334 time(s)
Long forms: 19

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
tyrosine kinase inhibitors
(3286 times)
Neoplasms
(1633 times)
EGFR (1105 times)
NSCLC (893 times)
CML (635 times)
1997 Inhibitors of tyrosine kinase.
TK inhibitors
(16 times)
Neoplasms
(6 times)
TK (10 times)
EGFR (7 times)
TKs (5 times)
2003 The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer.
tyrosine kinases
(8 times)
Neoplasms
(3 times)
EGFR (2 times)
mAbs (2 times)
ADCC (1 time)
2009 Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
tyrosine kinase activity
(3 times)
Chemistry
(1 time)
EGFR (1 time)
mAbs (1 time)
MBC (1 time)
2011 The role of antiangiogenetic agents in the treatment of breast cancer.
tyrosine kinase receptor inhibitors
(3 times)
Pathology
(1 time)
EGFR (1 time)
FGFR1 (1 time)
FISH (1 time)
2013 Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
mTOR kinase inhibitors
(2 times)
Cell Biology
(2 times)
FAs (1 time)
FASN (1 time)
mTOR (1 time)
2008 Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
topological Kondo insulators
(2 times)
Biomedical Research
(1 time)
KIs (1 time)
MR (1 time)
SS (1 time)
2016 Surface Kondo effect and non-trivial metallic state of the Kondo insulator YbB12.
tyrosine kinase domain
(2 times)
Biotechnology
(1 time)
CCK-8 (1 time)
mAbs (1 time)
NSCLC (1 time)
2008 ErbB antagonists patenting: "playing chess with cancer".
tyrosine kinase receptors
(2 times)
Pharmacology
(1 time)
MTC (1 time)
2009 Multitarget drugs: the present and the future of cancer therapy.
10  EGFR-TK inhibitors
(1 time)
Toxicology
(1 time)
mAbs (1 time)
2017 Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma.
11  EGFR-tyrosine kinases
(1 time)
Neoplasms
(1 time)
EGFR (1 time)
PFS (1 time)
2017 Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
12  receptor kinase inhibitors
(1 time)
Neoplasms
(1 time)
ccRCC (1 time)
TKI (1 time)
2015 Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience.
13  targeted by RTK inhibitors
(1 time)
Neoplasms
(1 time)
RTK (1 time)
2015 The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
14  targets for specific kinase inhibitors
(1 time)
Veterinary Medicine
(1 time)
OSAs (1 time)
PDGFR (1 time)
2013 PDGFs and PDGFRs in canine osteosarcoma: new targets for innovative therapeutic strategies in comparative oncology.
15  TK domain inhibitors
(1 time)
Neoplasms
(1 time)
--- 2012 Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy.
16  treated with kinase inhibitors
(1 time)
Hematology
(1 time)
CML (1 time)
2011 Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia.
17  tyrosine kinase activity inhibitors
(1 time)
Chemistry
(1 time)
ABC (1 time)
SLC (1 time)
2015 Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia.
18  tyrosine kinase enzymatic activity
(1 time)
Thoracic Diseases
(1 time)
EGFR (1 time)
mAb (1 time)
NSCLC (1 time)
2011 Treatment of advanced non small cell lung cancer.
19  tyrosine kinase inhibitors treatments
(1 time)
Public Health
(1 time)
CML (1 time)
2017 Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.